Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

Hemagglutinin (HA) is most abundant glycoprotein on the influenza virus surface. Influenza
HA promotes viral entry by engaging the receptor and mediating virus–host membrane …

Summary The World Health Organization has declared the ongoing outbreak of COVID-19,
which is caused by a novel coronavirus SARS-CoV-2, a pandemic. There is currently a lack …

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show
protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the …

Many SARS-CoV-2 variants have mutations at key sites targeted by antibodies. However, it
is unknown if antibodies elicited by infection with these variants target the same or different …

Influenza virus has resurfaced recently from inactivity during the early stages of the COVID-
19 pandemic, raising serious concerns about the nature and magnitude of future epidemics …

Across decades of co-circulation in humans, influenza A subtypes H1N1 and H3N2 have
caused seasonal epidemics characterized by different age distributions of cases and …

Influenza viruses are responsible for millions of cases globally and significantly threaten
public health. Since pandemic and zoonotic influenza viruses have emerged in the last 20 …

Improved influenza vaccines are urgently needed to reduce the burden of seasonal
influenza and to ensure a rapid and effective public-health response to future influenza …

The development of vaccines, which prime the immune system to respond to future
infections, has led to global declines in morbidity and mortality from dreadful infectious …